Fundz

Barinthus Biotherapeutics plc

Oxford, England, United Kingdom · Biopharma, Biotechnology, Therapeutics

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP; Barinthus Bio is advancing a pipeline of four product candidates across a diverse ran

Key facts

Headquarters
Oxford, England, United Kingdom
Employees
33
Industries
Biopharma, Biotechnology, Therapeutics
Website
barinthusbio.com
LinkedIn
Company page

Recent activity at Barinthus Biotherapeutics plc

  • : SEC 8-K (5.01):
  • : SEC 8-K (8.01): On September 1, 2026, the High Court of Justice of England and Wales sanctioned the Scheme of Arrangement as part of the Agreement and Plan of Merger involving Barinthus Biotherapeutics plc, Beacon Topco, Inc., Cdog Merger Sub, Inc., and Clywedog Therapeutics, Inc. This approval is crucial for the merger process, with the Scheme expected to become effective on September 9, 2026. Following this sanction, Barinthus Biotherapeutics notified Nasdaq about the anticipated halt in trading of its American Depositary Shares (ADSs) prior to the opening on the effective date. The filing highlights ongoing plans for delisting and deregistration of the ADSs, emphasizing strategic moves in the company's operations amidst significant restructuring efforts.
  • : SEC 8-K (8.01): On August 24, 2026, Barinthus Biotherapeutics PLC reported a significant change in its management structure, officially disclosing the appointment of a new Chief Financial Officer (CFO) following the departure of the previous CFO. This change is expected to impact the company's financial strategies moving forward. The new CFO brings extensive experience in financial management within the biopharmaceutical sector, which may enhance the company's fiscal stability and investor confidence. The event occurred just one day prior to the filing date of this report, making it timely and relevant for stakeholders.
  • : SEC 8-K (8.01): The Company received an Extension Notice from Nasdaq on June 30, 2026, granting an additional 180 days until December 28, 2026, to comply with the Bid Price Requirement for its American Depositary Shares (ADSs), which had fallen below the minimum $1.00 per share for the past 30 consecutive business days. As part of this extension, the listing of the ADSs was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective July 2, 2026. The Company will monitor its ADS bid price closely and may consider actions such as a reverse stock split to regain compliance. While the extension allows for additional time, there is no guarantee that the Company will meet the requirements to avoid delisting.
  • : SEC 8-K (5.07): On May 20, 2026, Barinthus Biotherapeutics PLC registered American Depositary Shares (ADS) on The Nasdaq Global Market under the symbol BRNS. Each ADS represents one ordinary share, facilitating the rights to receive ordinary shares in the U.S. market. This move enhances the company's access to capital and visibility among investors, marking a significant strategic step as they position themselves in the biotechnology sector. The registration is part of an ongoing compliance with the Securities Act of 1933 and indicates an increased commitment to transparency and investor engagement.
  • : Barinthus Biotherapeutics Appoints Douglas Swirsky as Chief Financial Officer
  • : SEC 8-K (5.02): On April 22, 2026, Barinthus Biotherapeutics plc appointed Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026. Mr. Swirsky brings over 25 years of industry experience, having most recently served as CFO of MaxCyte, Inc. He will operate under a master services agreement with Grand Strand BioAdvisors LLC, for which he will receive a fee of $20,000 per month. The agreement includes provisions for liability insurance and indemnification. Notably, there are no disclosed family relationships or conflicting transactions related to his appointment.
  • : SEC 8-K (5.02): On March 27, 2026, Gemma Jones notified Barinthus Biotherapeutics plc that she will step down from her role as principal accounting officer, with an effective date of April 30, 2026. This change in management is significant as it involves the primary financial reporting officer of the company, which may impact investor confidence and strategic financial planning. The decision to resign appears to be part of broader shifts within the company, but specific reasons were not disclosed. The filing also includes typical forward-looking statements regarding potential risks and expectations related to the departure.
  • : Barinthus to merge with Clywedog for new firm
  • : SEC 8-K (7.01): On March 13, 2026, the Company released an update to its corporate presentation, which will be utilized in meetings with investors and analysts. This presentation has been furnished as Exhibit 99.2 in this 8-K filing. The Company cautions that it has no obligation to update or amend the presentation. The filing also mentions that in connection with a proposed transaction involving Clywedog Therapeutics Inc., a registration statement on Form S-4 will be filed with the SEC, which will include a joint proxy statement/prospectus detailing the transaction and critical information for investors and security holders. The event date for this update is March 13, 2026, indicating its relevance and timeliness for stakeholders.

Leadership

  • Alex Hammacher, Non Executive Director
  • Nick Fullenkamp, Vice President, Corporate Development
  • Douglas Swirsky, Principal
  • Leon Hooftman, Chief Medical Officer

Verified email and direct lines for Barinthus Biotherapeutics plc’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Barinthus Biotherapeutics plc files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Barinthus Biotherapeutics plc in the news

Companies similar to Barinthus Biotherapeutics plc

About Barinthus Biotherapeutics plc: questions and answers

What does Barinthus Biotherapeutics plc do?

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP; Barinthus Bio is advancing a pipeline of four product candidates across a diverse ran

Where is Barinthus Biotherapeutics plc headquartered?

Barinthus Biotherapeutics plc is headquartered in Oxford, England, United Kingdom.

How many employees does Barinthus Biotherapeutics plc have?

Barinthus Biotherapeutics plc has about 33 employees.

Who leads Barinthus Biotherapeutics plc?

Nick Fullenkamp is a Vice President, Corporate Development at Barinthus Biotherapeutics plc.

What is the latest news on Barinthus Biotherapeutics plc?

On Sep 09, 2026, SEC 8-K (5.01):

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Barinthus Biotherapeutics plc across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.